Elevated zonulin and stool sIgA indicate gut barrier breakdown and active mucosal immunity.

Intestinal barrier integrity and mucosal immunity are tightly regulated systems. The assessment of zonulin and secretory IgA (sIgA) provides a detailed snapshot of both the structural status of the gut lining and the activity of the immune system residing within the intestinal mucosa.

Intestinal permeability and zonulin mechanisms

Zonulin is the only known human protein that reversibly modulates intestinal permeability by regulating intercellular tight junctions.

• Molecular mechanism: Zonulin acts as a physiological modulator that binds to specific receptors on the intestinal epithelium, activating a protein kinase C-alpha (PKC-α) pathway. This triggers actin polymerization and the subsequent reorganization of the cytoskeleton, which physically pulls apart the tight junction proteins (such as zonula occludens-1 and occludin). This paracellular "opening" allows the translocation of luminal contents into the systemic circulation.
• Clinical evidence: Elevated zonulin levels are strongly associated with pathologies characterized by barrier dysfunction. Meta-analyses show significant elevations in patients with liver cirrhosis (mean effect size 0.590) and cardiovascular disease (standardized mean difference 1.74). In metabolic conditions like non-alcoholic steatohepatitis (NASH), zonulin demonstrates diagnostic accuracy of approximately 81.7% and correlates with the severity of fat accumulation in the liver.

Mucosal immune activation and secretory IgA

Secretory IgA (sIgA) is the primary mediator of the gut’s adaptive immune system, representing the first line of defense against pathogens and environmental toxins.

• Mechanism of action: sIgA is produced by antibody-secreting cells in the lamina propria and transcytosed into the gut lumen. Its primary role is "immune exclusion"—binding to pathogens, bacteria, and toxins to prevent them from adhering to and penetrating the intestinal wall.
• Evidence of activation: Elevated levels of fecal sIgA are indicative of an active mucosal immune response. Research shows that sIgA increases significantly during symptomatic parasitic infections and dysbiosis compared to asymptomatic states. In inflammatory bowel disease (IBD), the level of fecal IgA and the percentage of IgA-coated bacteria correlate closely with clinical and endoscopic activity scores, marking it as a sensitive indicator of active mucosal inflammation.

Bottom line

The claim is strongly supported by science. Elevated zonulin is a validated driver of increased intestinal permeability via tight junction disassembly, while elevated stool sIgA is a robust marker of mucosal immune engagement and the body’s attempt to neutralize luminal threats through immune exclusion.